Browsing by Author "Yolcu A."

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    A rare parasitic infection: visceral leishmaniasis case after gastric cancer treatment
    (Springer-Verlag Wien, 2018) Yolcu A.; Dirican A.; Ozturk G.G.; Cetin C.B.; Aydogdu I.
    We present a case of Visceral Leishmaniasis (VL) in a patient with gastric cancer treated with chemoradiotherapy. A 69-year-old man with gastric carcinoma had been treated with total gastrectomy, lymphadenectomy and postoperative radiotherapy with chemotherapy. Then 3 years after treatment, due to pancytopenia with progressive trombocytopenia and splenomegaly, bone marrow examination was performed and Leishmania spp. amastigotes were diagnosed. When antibiotherapy was completed, splenomegaly was eliminated and the laboratory results became normal. VL should be kept in mind in the differential diagnosis of patients, even adults, with splenomegaly, trombocytopenia and a history of contact with dogs in endemic countries such as Turkey. © 2018, Springer-Verlag GmbH Austria, part of Springer Nature.
  • No Thumbnail Available
    Item
    Amlodipine-induced gingival hypertrophy
    (Elsevier B.V., 2020) Yolcu A.; Aydogdu I.
    [No abstract available]
  • No Thumbnail Available
    Item
    Signet-ring plasma cells
    (Massachussetts Medical Society, 2020) Yolcu A.; Aydogdu I.
    [No abstract available]
  • No Thumbnail Available
    Item
    Langerhans cell histiocytosis: A rare cause of pathological rib fracture
    (Baycinar Medical Publishing, 2021) Yolcu A.; Tulay C.M.; Temiz P.; Aydoğdu İ.
    Langerhans cell histiocytosis, formerly known as histiocytosis X, represents clonal proliferations of the antigen-presenting dendritic cells, which are normally found in many organs. It is a rare disease which tends to affect children and adolescents. In particular, adult-onset type is very rare. Herein, we present a female adult diagnosed with Langerhans cell histiocytosis of the rib without any systemic involvement which was successfully treated with surgery. © 2021. All right reserved by the Turkish Society of Cardiovascular Surgery.
  • No Thumbnail Available
    Item
    Acquired Hemophilia A In Adults: A Multicenter Study from Turkey
    (Springer, 2023) Arslan Davulcu E.; Demirci Z.; Yılmaz U.; Ar M.C.; Teke H.Ü.; Karakuş V.; Çiftçiler R.; Selim C.; Yavaşoğlu İ.; Durusoy S.S.; Okan V.; Akdeniz A.; Yolcu A.; Aydoğdu İ.; Güney T.; Yılmaz A.F.; Şahin F.
    Acquired hemophilia A (AHA) is a rare disease caused by autoantibodies inhibiting factor VIII (FVIII) activity. Although the conditionis usually idiopathic, there may be other underlying diseases. Treatment consists of two steps: treatment of acute bleeding and immunosuppression. In this multicenter study, we aimed to demonstrate the clinical characteristics, management details, and survival of AHA patients in Turkey. Data was collected from eleven centers in Turkey. aPTT, FVIII, FVIII inhibitor, and hemoglobin (HB) levels, mixing test results, and demographics at diagnosis, treatment information, adverse events, bleeding episodes during follow-up, relapses, and outcome were analyzed. Twenty-nine patients were analyzed (58.6% female). No underlying disorder could be detected in 14 patients. The most prevalent etiologies were pregnancy, malignancy and infections. The median FVIII activity and FVIII inhibitor titer at diagnosis were 0.7% (0.0–29.4%) and 32.6 BU (0.6–135.6 BU) respectively. Bleeding was severe in 44.8% of patients. The HB value was significantly lower in patients with severe bleeding. Most of the patients (n = 25, 86.2%) had only one bleeding episode without relapse, three patients (10.3%) had two bleeding episodes, and one patient had more than three bleedings. 21 (75%) patients received hemostatic therapy. The use of recombinant FVIIa was slightly higher than activated prothrombin complex concentrate (15 versus 10 patients). Immunosuppressive treatment was initiated in 26 (93%) patients. Regimens containing steroid, cyclophosphamide, and rituximab in different combinations were the most preferred. The median follow-up period was 13 months (2–156 months). Median overall survival was 154.97 months. Four and six-year survival were 90.9 ± 0.8% and 77.9 ± 14.1% respectively. This is a unique study that investigated the demographic characteristics, treatment approaches, and patient survival of AHA in Turkey. © 2022, The Author(s), under exclusive licence to Indian Society of Hematology and Blood Transfusion.